The UK Parkinson’s Disease Clinical Studies Group (UK PD-CSG) unites Parkinson’s researchers across the whole of the UK. The Group is composed of research interested clinicians and clinician scientists from diverse disciplines with patient and public involvement representative members. The UK PD-CSG works together to promote research to develop better treatments and care for people affected by Parkinson’s. We are keen to work with industry to support early feasibility assessments, and quickly identify sites with capacity to deliver their trial.
Logistical Advice
The group can give up to date, accurate advice on whether a study would be feasible for the research delivery staff within the NHS and clinical community. The group has extensive experience working with NHS Trusts across the UK.
Information Sharing
Comprehensive knowledge of infrastructure, capacity and eligibility of existing sites
Geographical Distribution
Information about potential future study sites to aid more even geographical distribution of clinical trials across the UK
Quality of Research
Support training of researchers
Promote more standardised clinical trial activities across UK sites
Efficiency
More efficient communication
Facilitate faster setup processes with fewer delays
Cost Saving
More rapid delivery of clinical trials through increased workforce qualified to undertake Parkinson's clinical trials across the UK
Support for New Sites
Support for sites less experienced in clinical research through UK PD-CSG Buddy Scheme with more experienced sites and other measures
Support for Parkinson's Professionals New to Research
Opportunity for one to one advice sessions with more experienced UK PD-CSG members
Provide training opportunities
Potential group PPI session with UK PD CSG PPI Members
Apply to attend a session with our expert PPI group for feedback on protocol designs
Interested in collaborating?
Contact Emma Fargher
Group membership represents research sites across the whole of the UK. By working directly with investigators, we can provide accurate and up-to-date information, and implement strategies to increase capacity or develop capabilities to support Parkinson’s studies. We encourage commercial sponsors to engage with the Group at the earliest stages of development, to ensure we can feed into study designs and ensure they will be deliverable in the UK.